Introduction
============

*Helicobacter pylori* can be resistant to the acidic conditions of the stomach and colonizes the gastric epithelium by producing urease.[@b1-copd-11-2055] This microorganism also causes gastric inflammation by various virulence factors such as vacuolating cytotoxin A, cytotoxin-associated gene product A, and neutrophil-activating protein A.[@b1-copd-11-2055],[@b2-copd-11-2055] *H. pylori* infection is a major cause of gastric diseases such as chronic active gastritis, peptic ulcer disease, and mucosa-associated lymphoid tissue lymphoma.[@b3-copd-11-2055]--[@b5-copd-11-2055] Infection with *H. pylori* can be detected by gastric mucosal biopsy, a rapid urease test, and simple serologic tests. Despite the limitations of serologic testing for *H. pylori* infection, this technique has been widely used because it is simple and noninvasive.

Interestingly, *H. pylori* infection may not be restricted to the stomach. Since the first report that coronary heart disease might be associated with *H. pylori* seropositivity in 1994,[@b6-copd-11-2055] several studies on the implications of *H. pylori* infection in various diseases outside the gastrointestinal system have been published. Such systems include the cardiovascular, neurological, dermatological, immunological, hematological, hepatobiliary, ophthalmological, endocrinological, and gynecological systems.[@b7-copd-11-2055]--[@b9-copd-11-2055]

Until now, the extragastrointestinal implications of *H. pylori* infection have been hypothesized to be associated with systemic inflammation, which might in turn be associated with *H. pylori*-induced gastric inflammation. The chronic gastric inflammatory response induces systemic inflammation and immune responses by altering the polarized T-helper 1 and 2 responses. However, whether *H. pylori*-induced inflammation plays a role in the pathogenesis of extragastric diseases remains unclear.[@b10-copd-11-2055]

An association between *H. pylori* infection and respiratory disease has recently been reported.[@b11-copd-11-2055] Bronchiectasis, tuberculosis, and lung cancer are reportedly associated with higher *H. pylori* seroprevalence.[@b12-copd-11-2055] However, several epidemiological studies have shown an inverse relationship between *H. pylori* infection and the incidence of allergic airway diseases including asthma.[@b10-copd-11-2055],[@b13-copd-11-2055],[@b14-copd-11-2055] A few studies, including some with small study samples, have identified a potential association between *H. pylori* infection and COPD. The prevalence of *H. pylori* seropositivity was found to be higher in patients with COPD than in those without COPD.[@b15-copd-11-2055],[@b16-copd-11-2055] Also, a significant relationship between *H. pylori* seropositivity and the forced expiratory volume in 1 second (FEV~1~) was recently demonstrated.[@b17-copd-11-2055] However, considering that the prevalence of *H. pylori* infection exhibits regional variability,[@b18-copd-11-2055] we suspected that the clinical impact of *H. pylori* infection on the prevalence of COPD and lung function may differ according to the regional prevalence of *H. pylori*. Nevertheless, until now, no reports have addressed the association between *H. pylori* infection and COPD and the impact of *H. pylori* infection on lung function in Asian countries with a high burden of *H. pylori* infection.

In this study, we aimed to elucidate the association between *H. pylori* infection and the presence of mild to moderate COPD in an Asian country with high prevalence of *H. pylori* infection. We also aimed to identify the impact of *H. pylori* infection on declining lung function in patients with COPD.

Methods
=======

Study population
----------------

For this case--control study, we recruited participants aged ≥40 years who underwent a medical checkup and serologic test for *H. pylori* at Seoul Metropolitan Government--Seoul National University Boramae Medical Center from January 2013 to February 2015. Routine checkups during the study period also included esophagogastroduodenoscopy (EGD), spirometry, and a basic demographic questionnaire.

The patients' information was obtained from the clinical records and anonymized prior to analysis. The Institutional Review Board of Seoul Metropolitan Government--Seoul National University Boramae Medical Center approved the study protocol (IRB No 16-2015-40/041) however informed consent was not sought as per IRB requirements with retrospective studies.

Selection of cases and controls
-------------------------------

Among the participants who underwent a medical checkup and serology test for *H. pylori*, patients with mild to moderate COPD were selected as cases and participants without airflow limitation on spirometry were regarded as controls.

Mild to moderate COPD was defined as a prebronchodilator FEV~1~/forced vital capacity (FVC) ratio of \<0.7 and FEV~1~ (% predicted) of ≥50%; patients with these values were assigned to the case group. Participants with an FEV~1~/FVC ratio of ≥0.7 were assigned to the control group. Age- and sex-matched controls were randomly selected at a control:case ratio of 2:1.

We excluded participants with allergic diseases such as asthma or allergic rhinitis as well as those with lung diseases that may contribute to airflow limitations such as lung cancer, pulmonary tuberculosis, and bronchiectasis involving more than one lobe.

The following clinical information was collected: age, sex, body mass index, comorbidities, smoking status, spirometric and laboratory data, radiographic findings, and EGD findings.

Among 236 patients with a defined airflow limitation, 35 patients were excluded as follows: 14 patients with asthma, eight patients with bronchiectasis involving more than one lobe, two patients with lungs destroyed by tuberculosis, one patient with empyema, four patients without available EGD data, five patients with severe COPD characterized by an FEV~1~ of \<50%, and one patient without a matched control. Finally, 201 patients with mild to moderate COPD and their 402 matched controls were included in this analysis.

Measurements
------------

### Seropositivity and rapid urease test for *H. pylori* infection

*H. pylori*-specific immunoglobulin G (IgG) concentrations were measured with a commercially available enzyme-linked immunosorbent assay (DIESSE Diagnostica Senese, Siena, Italy) according to the manufacturer's protocol. The lower limit of a positive *H. pylori* IgG titer was 20 units/mL. To determine the *H. pylori* infection status, a rapid urease test (CLO test; Ballard Medical Products, Draper, UT, USA) was performed at the time of endoscopy with a gastric mucosa specimen obtained by endoscopic biopsy. The CLO test was positive when the gel pellet turned dark pink to magenta color for up to 24 hours.

### Spirometry and annual rate of lung function decline

Spirometry was performed according to the criteria of the American Thoracic Society.[@b19-copd-11-2055] The method described by Morris[@b20-copd-11-2055] was used for the predicted FEV~1~ and FVC. Prebronchodilator spirometry data were used for analysis because postbronchodilator testing is not performed in Korea. To assess the annual decline in lung function, we collected the participants' spirometry data if they had undergone spirometry more than three times per year since January 2010.

Statistical analysis
--------------------

The chi-square test was used to compare categorical variables, a *t*-test was used to compare normally distributed continuous data, and the Wilcoxon rank sum test was used to compare non-normally distributed continuous variables. The associations between the *H. pylori* IgG level and various pulmonary function parameters were investigated using Pearson's correlation coefficient. Multivariable association analysis was performed with logistic regression analyses, adjusting for sex, age, smoking status, gastric diseases known to be related to *H. pylori* infection, and the severity of airflow limitation as defined by FEV~1~. Concordance between the CLO test result and IgG seropositivity for *H. pylori* infection was analyzed with the kappa index. Decline in FEV~1~ or FVC over time was analyzed with random-slope, random-intercept mixed linear regression, adjusting for age, sex, body mass index, smoking status, and baseline FEV~1~ or FVC. All statistical analyses were performed using Statistical Package for the Social Sciences for Windows (version 22.0; IBM Corporation, Armonk, NY, USA) and Stata software (version 12.1; StataCorp LP, College Station, TX, USA).

Results
=======

Baseline characteristics of the study population
------------------------------------------------

In total, 603 participants (201 patients with COPD and 402 controls) were analyzed in this study. The baseline characteristics of the study population are listed in [Table 1](#t1-copd-11-2055){ref-type="table"}. The participants' mean age was 60 years, and most of them were men (87.1%). The mean FEV~1~ of patients with COPD was 88.60%±14.9% of predicted, and nonsmokers comprised 15.4% of all patients with COPD. Hypertension and diabetes were the most common comorbidities and were suggested to be associated with *H. pylori* infection. The prevalence rates of these suggested comorbidities were not significantly different between the cases and controls.

*H. pylori* seropositivity and COPD
-----------------------------------

As shown in [Table 2](#t2-copd-11-2055){ref-type="table"}, IgG seropositivity for *H. pylori* was present in about half the participants in each group without a significant difference (cases, 45.8%; controls, 52.2%; *P*=0.13). Also, in a quantitative comparison of the association between the IgG level of *H. pylori* and the presence of COPD, no significant difference was found between the two groups (cases, 114.8 units/mL; controls, 109.6 units/mL; *P*=0.55) ([Table 2](#t2-copd-11-2055){ref-type="table"}; [Figure 1](#f1-copd-11-2055){ref-type="fig"}).

In a comparison of the concordance between *H. pylori* seropositivity and the CLO test results, 71 of 89 (79.8%) with a positive CLO test result showed *H. pylori* seropositivity and 99 of 147 (67.3%) patients with a negative CLO test result showed *H. pylori* seronegativity (kappa index, 0.442; *P*\<0.001) ([Table 3](#t3-copd-11-2055){ref-type="table"}). The discordant fractions between the two tests were not different in either group (kappa index for cases, 0.407; kappa index for controls, 0.464; *P*\<0.001 for both) ([Table 3](#t3-copd-11-2055){ref-type="table"}).

*H. pylori* seropositivity and severity of air flow limitation
--------------------------------------------------------------

When the airflow limitation (FEV~1~) in patients with COPD was graded using the Global Initiative for Chronic Obstructive Lung Disease criteria, there was no significant difference in *H. pylori* seropositivity between patients with stage 1 and stage 2 COPD (46.1% and 44.9%, respectively; *P*=0.89 for all comparisons). In addition, no relationship between the serum level of IgG for *H. pylori* and FEV~1~ was found in the cases or controls, or among the entire study population (n=187, *r*=−0.07, *P*\>0.05) ([Figure 2](#f2-copd-11-2055){ref-type="fig"}). Using an absolute value of FEV~1~, there was no relationship between the serum level of IgG for *H. pylori* and FEV~1~ (n=187, *r*=−0.026, *P*=0.729).

Multivariate analysis of the association between *H. pylori* infection and COPD
-------------------------------------------------------------------------------

The presence of *H. pylori* infection was evaluated by seropositivity and the CLO test. Therefore, the association between *H. pylori* infection and COPD was tested with respect to seropositivity and the CLO test results.

The univariate analysis of associations with seropositivity revealed that smoking status, presence of cardiovascular disease, gastric diseases including gastritis and peptic ulcer disease, and COPD were not associated with *H. pylori* seropositivity, while gastroesophageal reflux disease (GERD) showed a significant negative association with *H. pylori* seropositivity ([Table 4](#t4-copd-11-2055){ref-type="table"}). After adjustment for smoking status, presence of cardiovascular disease, presence of endoscopic gastritis and peptic ulcers, and GERD, we found that COPD was not associated with *H. pylori* seropositivity in this analysis. Only GERD was negatively associated with *H. pylori* seropositivity.

A total of 232 (38.5%) study participants underwent the CLO test because it was performed at the discretion of the endoscopist. Of these 232 patients, 89 (38.4%) showed CLO positivity. The CLO test was not associated with COPD, smoking status, the presence of cardiovascular disease, or the presence of gastric disease. However, GERD tended to be associated with a lower rate of CLO positivity.

Impact of *H. pylori* seropositivity on lung function decline
-------------------------------------------------------------

A total of 195 participants (51 cases, 144 controls) underwent spirometry three or more times per year. Among them, 93 (47.7%) exhibited *H. pylori* seropositivity. Because the final trends were not different between cases and controls, we assessed the association between *H. pylori* seropositivity and the decline in lung function in the total study population. Even in the whole study population, there was no difference in the annual rate of decline in the FEV~1~ between the *H. pylori*-seropositive and -seronegative groups (7.8±6.8 and 6.8±6.6 mL/year, respectively; *P*=0.92) ([Table 5](#t5-copd-11-2055){ref-type="table"}; [Figure 3](#f3-copd-11-2055){ref-type="fig"}). Similarly, the annual rate of decline in the FVC was not different between the *H. pylori*-seropositive and -seronegative groups (28.9±8.7 and 27.4±8.5 mL/year, respectively; *P*=0.90).

Discussion
==========

The seroprevalence of *H. pylori* among patients with COPD was not different from that of healthy controls in this study. Also, *H. pylori* seropositivity did not accelerate the annual rate of lung function decline during the 3-year follow-up period. This indicates that the seroprevalence of *H. pylori* might not be associated with the incidence and progression of COPD in countries with a high burden of *H. pylori* infection. Our results regarding lung function decline are consistent with a recent large cohort study that demonstrated no difference in the annual rate of lung function decline between seropositive and seronegative individuals.[@b17-copd-11-2055]

Although a few studies have suggested a cross-sectional relationship between *H. pylori* seroprevalence and COPD, there is no definitive evidence of a causal pathophysiologic association between *H. pylori* and COPD. Moreover, compared to the two previous studies, our study included relatively healthy patients because we used data from participants in an annual health screening program. GERD and cigarette smoking have been suggested as important confounding factors that explain this inconsistent seroprevalence in patients with COPD. As in the present study, many epidemiological studies have demonstrated a negative association between *H. pylori* infection and GERD.[@b21-copd-11-2055],[@b22-copd-11-2055] However, according to the epidemiologic reports of COPD, GERD is one of the most common comorbidities in patients with COPD, especially advanced-stage COPD.[@b23-copd-11-2055],[@b24-copd-11-2055] This inverse relationship among COPD, GERD, and *H. pylori* infection is related to the inconsistent seroprevalence of *H. pylori* in patients with COPD. Nevertheless, because only patients with mild to moderate COPD were recruited in this study, the impact of COPD severity on the prevalence of GERD and *H. pylori* infection may be minimal.

Cigarette smoking might also have an ambivalent influence on the association between COPD and *H. pylori* infection. Smoking is a major risk factor for the development of COPD, but whether *H. pylori* infection is associated with smoking remains unclear. Both higher and lower seropositivity of *H. pylori* have been reported in smokers compared with nonsmokers.[@b25-copd-11-2055]--[@b28-copd-11-2055]

Seropositivity was relatively high in the present study (up to half of the patients with COPD), similar to the general population of Korea.[@b29-copd-11-2055],[@b30-copd-11-2055] Therefore, *H. pylori* infection is so common that it may have only a modest effect on the incidence and disease progression of COPD in countries with a high burden of *H. pylori* infection, even if it is a real contributor.

Another point should be considered when interpreting the results of studies on the seroprevalence of *H. pylori* and its extragastric manifestations, that is, the limitations of seropositivity testing for *H. pylori* infection. As shown in this study, there is a discrepancy between the serum *H. pylori* IgG level and the CLO test results. Although serum *H. pylori* IgG measurement is a clinically useful noninvasive diagnostic test for *H. pylori* infection, some studies have shown that it has lower accuracy than the 13C urea breath test and exhibits disagreement with the histopathological findings (kappa statistic, 0.72; accuracy, 86%).[@b31-copd-11-2055]--[@b33-copd-11-2055]

This study has some strengths in terms of investigating the role of *H. pylori* in patients with COPD. First, to the best of our knowledge, this is the first report on the association between *H. pylori* seroprevalence and the prevalence of COPD, and between *H. pylori* seroprevalence and annual lung function decline in a country with a high burden of *H. pylori* infection. Also, because the study population was recruited from among individuals who participated in an annual health screening program and were thought to be relatively healthy, the participants' characteristics are considered to be very similar to those of the Korean general population with respect to the prevalence of diseases such as diabetes mellitus and hypertension, despite the fact that the study population was small.[@b34-copd-11-2055],[@b35-copd-11-2055] Furthermore, the *H. pylori* seropositivity rate was similar to that in previous reports on Korean populations.[@b29-copd-11-2055],[@b30-copd-11-2055],[@b36-copd-11-2055] This indicates that our study population was minimally affected by selection bias.

Second, this study focused on patients with mild to moderate COPD. In patients with advanced COPD, GERD is a common comorbidity and may be associated with lung hyperinflation, increased abdominal pressure, and a high rate of medical treatment for COPD.[@b37-copd-11-2055] Therefore, in patients with advanced COPD, the actual association between *H. pylori* infection and COPD may be affected by GERD. This suggests that the present study may provide more reliable data regarding the association between *H. pylori* seroprevalence and COPD.

Third, we tested the participants for *H. pylori* infection using both the CLO test and serologic tests. Our results were consistent using both methods, indicating that the data of this study are reliable.

Despite these merits and interesting results, this study had some limitations. First, the study design prevented evaluation of additional contributing factors related to the causal role of *H. pylori* in the pathogenesis of COPD. Second, the small sample size may be an obstacle to generalize the results to the general population. Third, the follow-up period may have been too short to fully elucidate the rate of decline in lung function, and we could not evaluate the change in the annual decline in lung function after *H. pylori* eradication. Although 3 years may be a rather short period, we thought it was possible to identify a rapid or slower decline even with a 3-year follow-up period. Moreover, there is uncertainty regarding *H. pylori* infection at the first FEV~1~ measurement, even though we used spirometry data within a couple of years from the time the serology test was performed. Finally, the effects of respiratory medications on the decline in lung function were not considered because we could not verify the use of respiratory medications.

In conclusion, this study demonstrated no association between *H. pylori* infection and mild to moderate COPD in a country with a high burden of *H. pylori* infection. Furthermore, *H. pylori* infection did not affect the rate of decline in lung function in this study population.
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![*Helicobacter pylori* serum IgG levels in COPD patients and control subjects.\
**Note:** Displayed as median ± IQR.\
**Abbreviations:** IgG, immuno globulin G; IQR, interquartile range.](copd-11-2055Fig1){#f1-copd-11-2055}

![Correlation between *Helicobacter pylo* IgG titer and FEV~1~.\
**Notes:** The distribution of *H. pylori* IgG titer according to the airflow limitation. Linear regression of the *H. pylori* IgG versus FEV~1~ (%). No significant correlation was found between two variables (n=187, *r*=−0.071, *P*=0.333).\
**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; IgG, immunoglobulin G.](copd-11-2055Fig2){#f2-copd-11-2055}

![Impact of *Helicobacter pylori* seropositivity on lung function decline.\
**Notes:** (**A**) FEV~1~ decline and (**B**) FVC decline.\
**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity.](copd-11-2055Fig3){#f3-copd-11-2055}

###### 

Baseline clinical characteristics of COPD patients and control group

  Characteristics              COPD (n=201)      Control (n=402)     *P*-value
  ---------------------------- ----------------- ------------------- ------------------------------------------------------
  Age, years                   60.68±8.24        60.68±8.23          
  Male (%)                     175 (87.1)        350 (87.1)          
  Body mass index, kg/m^2^     24.07±3.02        24.16±2.73          0.685[\*](#tfn2-copd-11-2055){ref-type="table-fn"}
  Height                       1.68±0.069        1.67±0.069          0.095[\*](#tfn2-copd-11-2055){ref-type="table-fn"}
  Smoking status (%)                                                 \<0.001
   Current smoker              73 (36.3)         86 (21.4)           
   Exsmoker                    95 (47.3)         166 (41.3)          
   Nonsmoker                   31 (15.4)         144 (35.8)          
  Median pack-years (IQR)      25 (15.0--40.0)   20.0 (12.5--35.0)   0.312
  Spirometry                                                         
   FEV~1~                      2.58±0.59         3.04±0.53           \<0.001[\*](#tfn2-copd-11-2055){ref-type="table-fn"}
   FEV~1~(%)                   88.6±14.94        106.0±13.02         \<0.001[\*](#tfn2-copd-11-2055){ref-type="table-fn"}
   FVC                         3.91±0.812        3.83±0.66           0.241[\*](#tfn2-copd-11-2055){ref-type="table-fn"}
   FVC (%)                     96.8±13.52        96.6±11.27          0.833[\*](#tfn2-copd-11-2055){ref-type="table-fn"}
   FEV~1~/FVC                  65.91±6.18        79.45±5.13          \<0.001[\*](#tfn2-copd-11-2055){ref-type="table-fn"}
  Hypertension (%)             59 (29.4)         121 (30.1)          0.850[\*\*](#tfn3-copd-11-2055){ref-type="table-fn"}
  Diabetes mellitus (%)        27 (13.5)         67 (16.7)           0.313[\*\*](#tfn3-copd-11-2055){ref-type="table-fn"}
  Chronic kidney disease (%)   1 (0.5)           10 (2.5)            0.111[\*\*](#tfn3-copd-11-2055){ref-type="table-fn"}
  Iron deficiency anemia (%)   0 (0)             2 (0.5)             0.555[\*\*](#tfn3-copd-11-2055){ref-type="table-fn"}
  Cardiovascular disease (%)                                         0.711[\*\*](#tfn3-copd-11-2055){ref-type="table-fn"}
   Coronary artery disease     3 (1.5)           8 (2.0)             
   Cerebrovascular disease     2 (1.0)           2 (0.5)             

**Notes:** Continuous data are shown as mean ± SD,

*P*-value from *t*-test,

*P*-value from Fisher's exact test.

**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; IQR, interquartile range; SD, standard deviation.

###### 

The prevalence of positive *Helicobacter pylori* serology by COPD stage

                                                 COPD (n=201)          Control (n=402)       *P*-value
  ---------------------------------------------- --------------------- --------------------- -----------
  *H. pylori* IgG seropositivity n(%)            92 (45.8)             210 (52.2)            0.134
  *H. pylori* IgG level, units/mL Median (IQR)   114.8 (33.6--191.0)   109.6 (34.3, 166.4)   0.549

**Notes:**

*P*-value from chi-squared test,

*P*-value from Mann-Whitney test.

**Abbreviations:** IgG, immunoglobulin G; IQR, interquartile range.

###### 

The association of seropositivity of *Helicobacter pylori* and CLO tests

                                *H. pylori* seropositive (119)   *H. pylori* seronegative (117)
  ----------------------------- -------------------------------- --------------------------------
  CLO positive patients (89)    71 (79.8%)                       18 (20.2%)
  CLO negative patients (147)   48 (32.7%)                       99 (67.3%)

**Notes:** Kappa index: 0.442, *P*\<0.001.

###### 

Univariate and multivariate analysis of *Helicobacter pylori* seropositivity

  Variables                Seropositivity         CLO positivity                                                                                         
  ------------------------ ---------------------- ---------------- ---------------------- ------- ---------------------- ------- ----------------------- -------
  Smoking                  0.857 (0.602--1.220)   0.391            0.909 (0.630--1.313)   0.612   1.304 (0.668--2.544)   0.464   1.296 (0.647--2.596)    0.464
  CVD                      1.510 (0.531--4.297)   0.440            1.340 (0.467--3.845)   0.586   0.991 (0.231--4.250)   0.990   0.900 (0.208--3.899)    0.888
  Gastritis/peptic ulcer   1.343 (0.761--2.371)   0.309            1.132 (0.629--2.037)   0.679   4.4 (0.532--36.372)    0.169   3.961 (0.468--33.519)   0.207
  GERD                     0.482 (0.322--0.721)   \<0.001          0.485 (0.321--0.733)   0.001   0.494 (0.241--1.013)   0.054   0.527 (0.254--1.091)    0.084
  COPD                     0.772 (0.550--1.084)   0.135            0.778 (0.546--1.108)   0.164   1.023 (0.597--1.755)   0.933   1.014 (0.577--1.781)    0.963

**Note:** *P*-value from multiple logistic regression analysis, adjusting for sex, age, smoking status, gastric diseases known to be related to *H. pylori* infection, and the severity of airflow limitation as defined by FEV~1~.

**Abbreviations:** CI, confidence interval; GERD, gastroesophageal reflux disease; OR, odds ratio; CVD, cardiovascular disease.

###### 

Impact of *Helicobacter pylori* test on the lung function decline

  Total (195)   *H. pylori* seropositive (93)   *H. pylori* seronegative (102)   *P*-value
  ------------- ------------------------------- -------------------------------- -----------
  FEV~1~ (SE)   7.8 mL/year (6.8)               6.8 mL/year (6.6)                0.92
  FVC (SE)      28.9 mL/year (8.7)              27.4 mL/year (8.5)               0.90

**Note:** Adjusted by age, sex, BMI, initial FEV~1~ or FVC, smoking status.

**Abbreviations:** BMI, body mass index; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; SE, standard error.
